Kaufman H E, Varnell E D
Antimicrob Agents Chemother. 1976 Dec;10(6):885-8. doi: 10.1128/AAC.10.6.885.
Treatment of established experimental keratitis caused by herpes simplex virus with 9-beta-d-arabinofuranosyladenine 5'-monophosphate (Ara-AMP) or 9-beta-d-arabinofuranosylhypoxanthine 5'-monophosphate (Ara-HxMP) showed that the Ara-AMP, in a concentration of 2 or 20%, had a significant effect on the keratitis but that 0.4% Ara-HxMP showed only minimal activity. Ara-AMP was also effective in the treatment of idoxuridine-resistant keratitis. No local toxicity with a high concentration (20%) of Ara-AMP was seen, but the duration of therapy was brief.
用9-β-D-阿拉伯呋喃糖基腺嘌呤5'-单磷酸酯(Ara-AMP)或9-β-D-阿拉伯呋喃糖基次黄嘌呤5'-单磷酸酯(Ara-HxMP)治疗由单纯疱疹病毒引起的已确诊实验性角膜炎,结果显示,浓度为2%或20%的Ara-AMP对角膜炎有显著疗效,而0.4%的Ara-HxMP仅显示出最小活性。Ara-AMP在治疗对碘苷耐药的角膜炎方面也有效。未观察到高浓度(20%)的Ara-AMP有局部毒性,但治疗持续时间较短。